Met as Prognostic Factor and Therapeutic Target in Pretreated Hepatocellular Carcinoma (HCC): Final Results of a Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)
暂无分享,去创建一个
C. Porta | B. Daniele | L. Rimassa | I. Borbath | H. Vlierberghe | G. Abbadessa | A. Santoro | S. Salvagni | J. V. Laethem | R. Roemeling | J. Laethem